Safety and Antiviral Activity of TPV in HCV and/or HBV HIV Coinfected Patients TDM Randomised Pilot Evaluation
This study has been terminated.
Sponsor:
Boehringer Ingelheim Pharmaceuticals
Information provided by:
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00447902
First received: March 14, 2007
Last updated: May 18, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130302094108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The main purposes of this study are: demonstrate the safety and efficacy of TPV/r among HCV or hepatitis B virus (HBV) co-infected HIV+population, three-class (NRTI, NNRTI, and PI) experienced, with documented resistance to more than one PI. Determine pharmacokinetic data in this co-infected population and potential utility of using therapeutic drug monitoring (TDM) in improving efficacy outcomes.
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: tipranavir Drug: ritonavir |
Phase 3 |
Study Type: | Interventional |
Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Primary Purpose: Treatment |
Official Title: | Safety and Antiviral Activity of TPV in Hepatitis C or Hepatitis B HIV Coinfected Patients - TDM Randomised Pilot Evaluation |
Resource links provided by NLM:
Further study details as provided by Boehringer Ingelheim Pharmaceuticals:
Primary Outcome Measures:
- Treatment Response at Week 48 [ Time Frame: 48 weeks ]Treatment response is a confirmed virologic response, defined as a viral load less than 50 copies/mL at two consecutive measurements at least 5 days apart, without death, permanent discontinuation, or introduction of a new antiretroviral
Secondary Outcome Measures:
- Virologic Response Defined as Viral Load <50 Copies/mL at Each Visit [ Time Frame: After 4 weeks of treatment until the end of the trial ]Virologic response defined as viral load less than 50 copies/mL
- Occurrence of Viral Load Less Than 400 Copies/mL at Weeks 24 and 48 [ Time Frame: 24 and 48 weeks ]
- Occurrence of Viral Load Less Than 400 Copies/mL at Each Visit [ Time Frame: After 4 weeks of treatment until the end of the trial ]
- Occurrence of ≥1 log10 Drop in Viral Load From Baseline at All Visits, Including Visits at Weeks 24 and 48 [ Time Frame: Baseline, 24 and 48 weeks ]Occurrence of greater than or equal to 1 log10 drop in viral load from baseline at all visits, including visits at Weeks 24 and 48
- Change in Viral Load From Baseline at Each Visit [ Time Frame: After 4 weeks of treatment until the end of the trial ]
- Time to Treatment Failure [ Time Frame: After Day 1 of treatment until the end of the trial ]For patients who never achieve a confirmed virologic response, time to treatment failure is defined as 0. For patients who achieve a confirmed virologic response, time to treatment failure is the earliest time of either: death, permanent discontinuation of the study drug or loss to follow-up, introduction of a new anti-retroviral drug to the regimen if it is not solely related to either toxicity or intolerance clearly attributable to a background drug, but not the study drug, or first ocurrence of a VL >50 copies/mL at two consecutive measurements after having achieved a VL <50 copies/mL.
- Time to New AIDS or AIDS Related Progression Event or Death [ Time Frame: After Day 1 of treatment until the end of the trial ]
- Change in CD4+ and CD8+ Cell Counts From Baseline to Week 48 [ Time Frame: after 2 weeks of treatment till Week 48 ]
- Change in Ratio of CD38+/CD8+ From Baseline to Week 48 [ Time Frame: after 2 weeks of treatment till Week 48 ]
- Tipranavir (TPV) and Ritonavir (RTV) Trough Concentrations at Week 2, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48 [ Time Frame: after 2 weeks of treatment till Week 48 ]
- Patients Adherence With Study Medication Based on Pill Count [ Time Frame: After 4 weeks of treatment until the end of the trial ]number of pills acturally taken devided by the planned number of pills the patient should take
- Occurrence of Tipranavir (TPV) Inhibitory Quotient (IQ) >60 at Each Visit Where TPV Concentration is Measured [ Time Frame: After 2 weeks of treatment until the end of trial ]
- Occurrence of Tipranavir (TPV) Trough Concentration >120 μM [ Time Frame: After 2 weeks of treatment until the end of trial ]
- Post-dose Tipranavir (TPV) and Ritonavir (RTV) Concentrations at Week 4 [ Time Frame: Week 4 ]
Enrollment: | 11 |
Study Start Date: | March 2007 |
Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
![](https://webarchive.library.unt.edu/web/20130302094108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- HIV-1 infected males or females at least 18 years of age.
- Three-class (Nucleoside reverse transcriptase inhibitor (NRTI), Non nucleoside reverse transcriptase inhibitor (NNRTI), and Protease inhibitor (PI)) treatment-experienced (a minimum of 3-months duration for each class) with resistance to more than one PI (on the screening resistance testing).
- CD4+ T lymphocyte count more than 50 cells/micro l and Human immunodeficiency virus 1 (HIV 1) viral load (VL) more than 1000 copies/mL at screening.
- Patients must have at least one of the following permutations of active antiretroviral (ARV) medications available and must be willing to use them in the optimized background regimen (OBR) for trial inclusion.
- Chronic hepatitis C Virus (HCV) infection demonstrated by HCV-ribonucleic acid (RNA) positivity or, Chronic hepatitis B (HB) infection demonstrated by anti HBc IgG Antibody and HB Surface Antigen positivity.
- Acceptable screening laboratory values that indicate adequate baseline organ function.
- alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < Division of AIDS (DAIDS) Grade 3.
- Acceptable medical history, as assessed by the investigator.
- Only the four acquired immunodeficiency syndrome (AIDS) defining events listed below are acceptable as long as the event has been cured for at least 2 weeks before screening (Visit 1). Patients with history of other AIDS defining events are not allowed into the trial. The acceptable prior AIDS defining events include: Candidiasis (bronchi, trachea, lungs, esophageal), Herpes simplex: chronic ulcer(s) (more than 1 months duration), bronchitis, pneumonitis, or esophagitis, Mycobacterium tuberculosis (pulmonary or extrapulmonary), Pneumonia including Pneumocystis jiroveci (formerly carinii) pneumonia.
- A reliable method of barrier contraception will be used by all female patients who are of reproductive potential, for at least three months prior to Visit 3, during the trial, and 30 days after completion or termination from the trial.
Exclusion Criteria:
- Prior tipranavir use.
- Known hypersensitivity to any of the ingredients to the tipranavir or ritonavir formulations.
- ARV medication naive.
- Genotypic resistance to Tipranavir (TPV) (defined as a TPV mutation score of more than 7).
- Patients on recent drug holiday, defined as off ARV medications for at least 7 consecutive days within the month prior to screening.
- Decompensated liver disease, including presence or history of ascites, variceal bleeding, or hepatic encephalopathy or having ever been diagnosed as having hepatic insufficiency of Child Pugh class B or C.
Female patients of childbearing potential who:
- have a positive serum pregnancy test at screening or during the study,
- are breast feeding,
- are planning to become pregnant,
- are not willing to use a barrier method of contraception, or
- are only willing to use an estrogen-containing medication, e.g., ethinyl estradiol, as a method of contraception.
- Use of investigational medications within 30 days before study entry or during the trial except for those investigational ARV drugs permitted during the trial as stated in inclusion criteria 6.
- Use of concomitant drugs that may significantly reduce plasma levels of the study medications.
- Use of immunomodulatory drugs or antineoplastic agents within 30 days before study entry or during the trial.
- Inability to adhere to the requirements of the protocol, including active substance abuse, as defined by the investigator.
- Anticipated need for an interferon-based regimen in the 48 weeks following the study entry.
- Any other or additional plausible cause for chronic liver disease, including the presence of other viruses known or suspected to cause hepatitis.
- Any active infection or neoplasm currently being treated.
![](https://webarchive.library.unt.edu/web/20130302094108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00447902
Locations
United States, California | |
1182.99.32 Boehringer Ingelheim Investigational Site | |
Beverly Hills, California, United States | |
United States, Florida | |
1182.99.31 Boehringer Ingelheim Investigational Site | |
Fort Lauderdale, Florida, United States | |
United States, Rhode Island | |
1182.99.12 Boehringer Ingelheim Investigational Site | |
Providence, Rhode Island, United States | |
United States, Texas | |
1182.99.1 Boehringer Ingelheim Investigational Site | |
Austin, Texas, United States | |
1182.99.4 Boehringer Ingelheim Investigational Site | |
Houston, Texas, United States | |
Argentina | |
1182.99.54001 | |
Capital Federal, Argentina | |
Brazil | |
1182.99.55002 Hospital DIA | |
Sacomã - São Paulo, Brazil | |
1182.99.55004 Unidade de Referência em doenças Infecciosas Preveníveis | |
Santo André, Brazil | |
1182.99.55001 Universidade Federal de Sao Paulo | |
Sao Paulo, Brazil | |
1182.99.55003 Centro de Referência e Treinamento - DST/AIDS | |
Vila Mariana - Sao Paulo, Brazil | |
France | |
1182.99.3301A Boehringer Ingelheim Investigational Site | |
Garches, France | |
1182.99.3306K Boehringer Ingelheim Investigational Site | |
Nantes, France | |
1182.99.3306G Boehringer Ingelheim Investigational Site | |
Nantes, France | |
1182.99.3310D Boehringer Ingelheim Investigational Site | |
Nice cedex 3, France | |
1182.99.3310C Boehringer Ingelheim Investigational Site | |
Nice cedex 3, France | |
1182.99.3310E Boehringer Ingelheim Investigational Site | |
Nice cedex 3, France | |
1182.99.3310F Boehringer Ingelheim Investigational Site | |
Nice cedex 3, France | |
1182.99.3310H Boehringer Ingelheim Investigational Site | |
Nice cedex 3, France | |
1182.99.3310G Boehringer Ingelheim Investigational Site | |
Nice cedex 3, France | |
1182.99.3304C Boehringer Ingelheim Investigational Site | |
Paris, France | |
1182.99.3304A Boehringer Ingelheim Investigational Site | |
Paris, France | |
1182.99.3302A Boehringer Ingelheim Investigational Site | |
Perpignan, France | |
Germany | |
1182.99.4909 Boehringer Ingelheim Investigational Site | |
Düsseldorf, Germany | |
Italy | |
1182.99.3912 Boehringer Ingelheim Investigational Site | |
Ancona, Italy | |
1182.99.3901 Boehringer Ingelheim Investigational Site | |
Milano, Italy | |
1182.99.3911 Boehringer Ingelheim Investigational Site | |
Milano, Italy | |
1182.99.3916 Boehringer Ingelheim Investigational Site | |
Milano, Italy | |
1182.99.3906 Boehringer Ingelheim Investigational Site | |
Pavia, Italy | |
Spain | |
1182.99.3402 | |
Barcelona, Spain | |
1182.99.3407 | |
Madrid, Spain |
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
Study Chair: | Boehringer Ingelheim | Boehringer Ingelheim Pharmaceuticals |
![](https://webarchive.library.unt.edu/web/20130302094108im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
Related Info 
![This link exits the ClinicalTrials.gov site](https://webarchive.library.unt.edu/web/20130302094108im_/http://clinicaltrials.gov/ct2/html/images/frame/exit.bmp)
Related Info 
![This link exits the ClinicalTrials.gov site](https://webarchive.library.unt.edu/web/20130302094108im_/http://clinicaltrials.gov/ct2/html/images/frame/exit.bmp)
No publications provided
Responsible Party: | Boehringer Ingelheim, Study Chair, Boehringer Ingelheim |
ClinicalTrials.gov Identifier: | NCT00447902 History of Changes |
Other Study ID Numbers: | 1182.99, EudraCT No.: 2005-005023-33 |
Study First Received: | March 14, 2007 |
Results First Received: | September 25, 2009 |
Last Updated: | May 18, 2012 |
Health Authority: | Argentina: A.N.M.A.T. (Administracion Nacional de Medicamentos, Alimentos Y Tecnología) Brazil: Agência Nacional de Vigilância Sanitária - ANVISA France: Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) Germany: Italy: Comitato Etico Locale per la Sperimentazione Clinica Osp. L. Sacco - Milano Portugal: INFARMED - Instituto Nacional da Farmácia e do Medicamento Parque da Saúde de Lisboa Av. do Brasil Lisboa Spain: United States: Food and Drug Administration |
Keywords provided by Boehringer Ingelheim Pharmaceuticals:
treatment experienced |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Antiviral Agents |
Ritonavir Tipranavir Anti-Infective Agents Therapeutic Uses Pharmacologic Actions HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents |
ClinicalTrials.gov processed this record on February 28, 2013